Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&A
Resolved · regulation · Occurred · Assessed · 1 sources
This assessment is dated 2026-09-12. Check what remains unresolved below before relying on it.
Which companies' revenue or costs change?
Acquired immunology pipelines from DICE, Morphic, and Merida drive $2.6 billion in H1 revenue, reducing Eli Lilly's concentration risk on GLP-1 drug franchises.
| Question | What the evidence establishes |
|---|---|
| What was reported? | Reported factEli Lilly's Immunology division delivered $2.6 billion in revenue during H1 2026, representing a 9% year-over-year increase. |
| What else was confirmed? | Reported factImmunology accounted for 6.1% of total Eli Lilly corporate revenue in the first half of 2026. |
| Does the valuation support acting? | Interpretation5 stored valuation assumptions for LLY; the latest is dated 2026-08-06. |
| What would change the assessment? | UnknownEli Lilly Q3 immunology sales figures — Quarterly commercial sales print for Ebglyss and Omvoh uptake. |
What would this event cost your holdings?
Apply your own hypothetical returns to current holding values. The calculator does not infer security effects from this event.
Test this event against my holdingsReported facts
- · Eli Lilly's Immunology division delivered $2.6 billion in revenue during H1 2026, representing a 9% year-over-year increase.
- · Immunology accounted for 6.1% of total Eli Lilly corporate revenue in the first half of 2026.
- · Growth was driven by Taltz alongside new products Ebglyss and Omvoh, and M&A integrations of DICE, Morphic, and Merida.
Public research record
Research framework · page evidenceCompleted event assessment
revenue diversification via immunology M&A integration
| Type | Claim | Scope |
|---|---|---|
| Assumption | Eli Lilly's Immunology division delivered $2.6 billion in revenue during H1 2026, representing a 9% year-over-year increase. | 2026-09-12 |
| Interpretation | revenue diversification via immunology M&A integration | LLY |
Countercase, invalidators, and sources
Ebglyss and Omvoh accelerate uptake across European and US formularies, pushing annual immunology revenue above $5.5B.
- · Eli Lilly Q3 immunology sales figures — Quarterly commercial sales print for Ebglyss and Omvoh uptake.
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s · 2026-09-11
What remains unresolved
- Base path
- Immunology maintains single-digit to low double-digit growth, providing cash flow diversification.
- Adverse path
- Competitive pricing pressure in IL-17 and IL-23 classes compresses gross margins across Taltz and Omvoh.
- Supportive path
- Ebglyss and Omvoh accelerate uptake across European and US formularies, pushing annual immunology revenue above $5.5B.
- · Eli Lilly Q3 immunology sales figures — Quarterly commercial sales print for Ebglyss and Omvoh uptake.this week
Evidence
- Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s2026-09-11
“Eli Lilly's Immunology division generated $2.6 billion in revenues in H1 2026, up 9% year-over-year, representing 6.1% of total revenues... strategic acquisitions of DICE, Morphic, and Merida”
Supports: Immunology revenue reached $2.6B in H1 2026 (+9% YoY) on DICE, Morphic, and Merida M&A